120017
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.6 Breast Cancer (Dove Med Press)
- 4.3 Clin Epidemiol
- 2.6 Cancer Manag Res
- 3.2 Infect Drug Resist
- 4.1 Clin Interv Aging
- 6.1 Drug Des Dev Ther
- 4.1 Int J Chronic Obstr
- 8.7 Int J Nanomed
- 2.5 Int J Women's Health
- 3.2 Neuropsych Dis Treat
- 2.4 OncoTargets Ther
- 2.6 Patient Prefer Adher
- 2.6 Ther Clin Risk Manag
- 3.1 J Pain Res
- 3.5 Diabet Metab Synd Ob
- 4.5 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 2.4 Pharmgenomics Pers Med
- 2.6 Risk Manag Healthc Policy
- 4.6 J Inflamm Res
- 2.3 Int J Gen Med
- 3.9 J Hepatocell Carcinoma
- 3.3 J Asthma Allergy
- 2.5 Clin Cosmet Investig Dermatol
- 3.0 J Multidiscip Healthc
已发表论文
基于多功能纳米载体系统的前列腺癌精准诊断与治疗新策略
Authors Tang Z, Shen S, Gu C, Li S, Ni J, Yang D, Mi Y
Received 5 November 2025
Accepted for publication 13 January 2026
Published 22 January 2026 Volume 2026:21 579436
DOI https://doi.org/10.2147/IJN.S579436
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Professor Eng San Thian
Zhonghao Tang,1,2,* Si Shen,1,2,* Chenwei Gu,1,2,* Sixin Li,1,2,* Jiang Ni,3,* Dongjie Yang,4 Yuanyuan Mi1
1Department of Urology, Affiliated Hospital of Jiangnan University, Wuxi, People’s Republic of China; 2Wuxi School of Medicine, Jiangnan University, Wuxi, People’s Republic of China; 3Department of Pharmacy, Affiliated Hospital of Jiangnan University, Wuxi, People’s Republic of China; 4Department of Pathology, Affiliated Hospital of Jiangnan University, Wuxi, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Dongjie Yang, Department of Pathology, Affiliated Hospital of Jiangnan University, Wuxi, People’s Republic of China, Email ydj_252@163.com Yuanyuan Mi, Department of Urology, Affiliated Hospital of Jiangnan University, Wuxi, People’s Republic of China, Email miniao1984@163.com
Abstract: Prostate cancer (PCa) is one of the most common malignancies in men worldwide, and its current diagnostic and therapeutic methods still face severe challenges in terms of specificity, efficacy, and toxicity. The emergence of nanotechnology provides a powerful platform to overcome these obstacles. Through the design of sophisticated nanocarriers, targeted delivery and controlled release of therapeutic agents, as well as the synergy of multiple treatment modalities, can be achieved, thereby significantly improving efficacy and reducing side effects. Meanwhile, nanotechnology shows great potential in developing highly sensitive diagnostic tools and theranostic platforms, laying the foundation for early detection and precise treatment of PCa. Although challenges such as scalability and safety remain to be addressed before clinical translation, nanotechnology is undoubtedly reshaping the landscape of PCa management and driving the field towards personalized medicine. This review aims to provide a systematic overview of significant advancements in nanotechnology for the diagnosis and treatment of PCa over the past three years. It focuses on innovative research in novel nanocarrier design, targeting strategies, and the construction of integrated diagnostic and therapeutic platforms. Furthermore, current challenges and future directions for clinical translation are discussed, with the aim of offering valuable insights and references for researchers and clinicians in this field.
Keywords: prostate cancer, nanocarriers, targeted delivery, theranostics
1Department of Urology, Affiliated Hospital of Jiangnan University, Wuxi, People’s Republic of China; 2Wuxi School of Medicine, Jiangnan University, Wuxi, People’s Republic of China; 3Department of Pharmacy, Affiliated Hospital of Jiangnan University, Wuxi, People’s Republic of China; 4Department of Pathology, Affiliated Hospital of Jiangnan University, Wuxi, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Dongjie Yang, Department of Pathology, Affiliated Hospital of Jiangnan University, Wuxi, People’s Republic of China, Email ydj_252@163.com Yuanyuan Mi, Department of Urology, Affiliated Hospital of Jiangnan University, Wuxi, People’s Republic of China, Email miniao1984@163.com
Abstract: Prostate cancer (PCa) is one of the most common malignancies in men worldwide, and its current diagnostic and therapeutic methods still face severe challenges in terms of specificity, efficacy, and toxicity. The emergence of nanotechnology provides a powerful platform to overcome these obstacles. Through the design of sophisticated nanocarriers, targeted delivery and controlled release of therapeutic agents, as well as the synergy of multiple treatment modalities, can be achieved, thereby significantly improving efficacy and reducing side effects. Meanwhile, nanotechnology shows great potential in developing highly sensitive diagnostic tools and theranostic platforms, laying the foundation for early detection and precise treatment of PCa. Although challenges such as scalability and safety remain to be addressed before clinical translation, nanotechnology is undoubtedly reshaping the landscape of PCa management and driving the field towards personalized medicine. This review aims to provide a systematic overview of significant advancements in nanotechnology for the diagnosis and treatment of PCa over the past three years. It focuses on innovative research in novel nanocarrier design, targeting strategies, and the construction of integrated diagnostic and therapeutic platforms. Furthermore, current challenges and future directions for clinical translation are discussed, with the aim of offering valuable insights and references for researchers and clinicians in this field.
Keywords: prostate cancer, nanocarriers, targeted delivery, theranostics